Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes. - Jamroze A; Liu X; Hou S; Li WJ; Yu H; Tracz A; Li Q; Nastiuk K; Chen X; Huang J; Lin K; Lu Y; et al. (BioRxiv : the preprint server for biology, 2025)